<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024712</url>
  </required_header>
  <id_info>
    <org_study_id>CIH-CAMS-CHL-020</org_study_id>
    <secondary_id>CDR0000643743</secondary_id>
    <nct_id>NCT01024712</nct_id>
  </id_info>
  <brief_title>Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Paclitaxel/Carboplatin Combined With Intermittent Gefitinib in Patients With Untreated Advanced Non-small Cell Lung Cancer: A Phase Ⅱa Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. Giving paclitaxel and carboplatin together with gefitinib may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of giving paclitaxel and&#xD;
      carboplatin together with gefitinib and to see how well it works in treating patients with&#xD;
      Stage IIIB or stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the efficacy, in terms of overall response, and safety of paclitaxel and&#xD;
           carboplatin in combination with intermittent gefitinib in patients with advanced&#xD;
           nonsquamous non-small cell lung cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the disease-control rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: Patients receive paclitaxel IV on day 1, carboplatin IV on day 2, and oral gefitinib&#xD;
      once daily on days 8-17. Treatment repeats every 21 days for 4 courses in the absence of&#xD;
      disease progression or unacceptable toxicity. After completion of 4 courses, patients with&#xD;
      complete response or partial response may continue maintenance therapy comprising oral&#xD;
      gefitinib once daily in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) at baseline,&#xD;
      during study treatment, and after completion of study treatment for quality-of-life study.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months for 2 years and&#xD;
      then every 4 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall-response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-control rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  No squamous cell carcinoma&#xD;
&#xD;
          -  Untreated Stage IIIB or IV disease not suitable for surgery or radiotherapy OR&#xD;
             patients with postoperative recurrence who had never been treated by chemotherapy&#xD;
&#xD;
          -  No history of smoking or light smoking (&lt; 10 packs a year and smoking abatement ≥ 15&#xD;
             years)&#xD;
&#xD;
          -  At least 1 measurable tumor mass (length &gt; 1.5 cm and width &gt; 1.0 cm)&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 2 x 10^9/L&#xD;
&#xD;
          -  Platelet count ≥ 100 x 10^9/L&#xD;
&#xD;
          -  ALT and AST ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤1.5 times ULN&#xD;
&#xD;
          -  Serum creatinine normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignant tumors within the past year except for basal cell or squamous cell&#xD;
             carcinoma of the skin, or in situ malignant cancer that has been completely resected&#xD;
&#xD;
          -  No history of allergic reaction to any component of the drugs in this study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 month since prior investigational drugs or medical devices&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy for this tumor&#xD;
&#xD;
          -  No concurrent liposomal paclitaxel&#xD;
&#xD;
          -  No other concurrent antitumor therapy (e.g., radiotherapy or surgical treatment)&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy drugs or anticancer Chinese herbs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi, MD, PhD</last_name>
      <phone>86-10-137-0125-1865</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2009</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

